Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence

Mary Jo Fackler, Christopher B Umbricht, Danielle Williams, Pedram Argani, Leigh Ann Cruz, Vanessa Merino, Wei Wen Teo, Zhe Zhang, Peng Huang, Kala Visvanathan, Jeffrey Marks, Stephen Ethier, Joe W. Gray, Antonio C Wolff, Leslie Cope, Saraswati Sukumar

Research output: Contribution to journalArticle

Abstract

To better understand the biology of hormone receptor-positive and -negative breast cancer and to identify methylated gene markers of disease progression, we carried out a genome-wide methylation array analysis on 103 primary invasive breast cancers and 21 normal breast samples, using the Illumina Infinium HumanMethylation27 array that queried 27,578 CpG loci. Estrogen and/or progesterone receptor-positive tumors displayed more hypermethylated loci than estrogen receptor (ER)-negative tumors. However, the hypermethylated loci in ER-negative tumors were clustered closer to the transcriptional start site compared with ER-positive tumors. An ER-classifier set of CpG loci was identified, which independently partitioned primary tumors into ER subtypes. A total of 40 (32 novel and 8 previously known) CpG loci showed differential methylation specific to either ER-positive or ER-negative tumors. Each of the 40 ER subtype-specific loci was validated in silico, using an independent, publicly available methylome dataset from the Cancer Genome Atlas. In addition, we identified 100 methylated CpG loci that were significantly associated with disease progression; the majority of these loci were informative particularly in ER-negative breast cancer. Overall, the set was highly enriched in homeobox containing genes. This pilot study shows the robustness of the breast cancer methylome and illustrates its potential to stratify and reveal biological differences between ER subtypes of breast cancer. Furthermore, it defines candidate ER-specific markers and identifies potential markers predictive of outcome within ER subgroups.

Original languageEnglish (US)
Pages (from-to)6195-6207
Number of pages13
JournalCancer Research
Volume71
Issue number19
DOIs
StatePublished - Oct 1 2011

Fingerprint

Estrogen Receptors
Methylation
Genome
Hormones
Breast Neoplasms
Recurrence
Genes
Neoplasms
Disease Progression
Atlases
Homeobox Genes
Progesterone Receptors
Computer Simulation
Breast

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. / Fackler, Mary Jo; Umbricht, Christopher B; Williams, Danielle; Argani, Pedram; Cruz, Leigh Ann; Merino, Vanessa; Teo, Wei Wen; Zhang, Zhe; Huang, Peng; Visvanathan, Kala; Marks, Jeffrey; Ethier, Stephen; Gray, Joe W.; Wolff, Antonio C; Cope, Leslie; Sukumar, Saraswati.

In: Cancer Research, Vol. 71, No. 19, 01.10.2011, p. 6195-6207.

Research output: Contribution to journalArticle

@article{9e802c716fc54699ba9e72a2b7f3e306,
title = "Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence",
abstract = "To better understand the biology of hormone receptor-positive and -negative breast cancer and to identify methylated gene markers of disease progression, we carried out a genome-wide methylation array analysis on 103 primary invasive breast cancers and 21 normal breast samples, using the Illumina Infinium HumanMethylation27 array that queried 27,578 CpG loci. Estrogen and/or progesterone receptor-positive tumors displayed more hypermethylated loci than estrogen receptor (ER)-negative tumors. However, the hypermethylated loci in ER-negative tumors were clustered closer to the transcriptional start site compared with ER-positive tumors. An ER-classifier set of CpG loci was identified, which independently partitioned primary tumors into ER subtypes. A total of 40 (32 novel and 8 previously known) CpG loci showed differential methylation specific to either ER-positive or ER-negative tumors. Each of the 40 ER subtype-specific loci was validated in silico, using an independent, publicly available methylome dataset from the Cancer Genome Atlas. In addition, we identified 100 methylated CpG loci that were significantly associated with disease progression; the majority of these loci were informative particularly in ER-negative breast cancer. Overall, the set was highly enriched in homeobox containing genes. This pilot study shows the robustness of the breast cancer methylome and illustrates its potential to stratify and reveal biological differences between ER subtypes of breast cancer. Furthermore, it defines candidate ER-specific markers and identifies potential markers predictive of outcome within ER subgroups.",
author = "Fackler, {Mary Jo} and Umbricht, {Christopher B} and Danielle Williams and Pedram Argani and Cruz, {Leigh Ann} and Vanessa Merino and Teo, {Wei Wen} and Zhe Zhang and Peng Huang and Kala Visvanathan and Jeffrey Marks and Stephen Ethier and Gray, {Joe W.} and Wolff, {Antonio C} and Leslie Cope and Saraswati Sukumar",
year = "2011",
month = "10",
day = "1",
doi = "10.1158/0008-5472.CAN-11-1630",
language = "English (US)",
volume = "71",
pages = "6195--6207",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence

AU - Fackler, Mary Jo

AU - Umbricht, Christopher B

AU - Williams, Danielle

AU - Argani, Pedram

AU - Cruz, Leigh Ann

AU - Merino, Vanessa

AU - Teo, Wei Wen

AU - Zhang, Zhe

AU - Huang, Peng

AU - Visvanathan, Kala

AU - Marks, Jeffrey

AU - Ethier, Stephen

AU - Gray, Joe W.

AU - Wolff, Antonio C

AU - Cope, Leslie

AU - Sukumar, Saraswati

PY - 2011/10/1

Y1 - 2011/10/1

N2 - To better understand the biology of hormone receptor-positive and -negative breast cancer and to identify methylated gene markers of disease progression, we carried out a genome-wide methylation array analysis on 103 primary invasive breast cancers and 21 normal breast samples, using the Illumina Infinium HumanMethylation27 array that queried 27,578 CpG loci. Estrogen and/or progesterone receptor-positive tumors displayed more hypermethylated loci than estrogen receptor (ER)-negative tumors. However, the hypermethylated loci in ER-negative tumors were clustered closer to the transcriptional start site compared with ER-positive tumors. An ER-classifier set of CpG loci was identified, which independently partitioned primary tumors into ER subtypes. A total of 40 (32 novel and 8 previously known) CpG loci showed differential methylation specific to either ER-positive or ER-negative tumors. Each of the 40 ER subtype-specific loci was validated in silico, using an independent, publicly available methylome dataset from the Cancer Genome Atlas. In addition, we identified 100 methylated CpG loci that were significantly associated with disease progression; the majority of these loci were informative particularly in ER-negative breast cancer. Overall, the set was highly enriched in homeobox containing genes. This pilot study shows the robustness of the breast cancer methylome and illustrates its potential to stratify and reveal biological differences between ER subtypes of breast cancer. Furthermore, it defines candidate ER-specific markers and identifies potential markers predictive of outcome within ER subgroups.

AB - To better understand the biology of hormone receptor-positive and -negative breast cancer and to identify methylated gene markers of disease progression, we carried out a genome-wide methylation array analysis on 103 primary invasive breast cancers and 21 normal breast samples, using the Illumina Infinium HumanMethylation27 array that queried 27,578 CpG loci. Estrogen and/or progesterone receptor-positive tumors displayed more hypermethylated loci than estrogen receptor (ER)-negative tumors. However, the hypermethylated loci in ER-negative tumors were clustered closer to the transcriptional start site compared with ER-positive tumors. An ER-classifier set of CpG loci was identified, which independently partitioned primary tumors into ER subtypes. A total of 40 (32 novel and 8 previously known) CpG loci showed differential methylation specific to either ER-positive or ER-negative tumors. Each of the 40 ER subtype-specific loci was validated in silico, using an independent, publicly available methylome dataset from the Cancer Genome Atlas. In addition, we identified 100 methylated CpG loci that were significantly associated with disease progression; the majority of these loci were informative particularly in ER-negative breast cancer. Overall, the set was highly enriched in homeobox containing genes. This pilot study shows the robustness of the breast cancer methylome and illustrates its potential to stratify and reveal biological differences between ER subtypes of breast cancer. Furthermore, it defines candidate ER-specific markers and identifies potential markers predictive of outcome within ER subgroups.

UR - http://www.scopus.com/inward/record.url?scp=80053356357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053356357&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-11-1630

DO - 10.1158/0008-5472.CAN-11-1630

M3 - Article

C2 - 21825015

AN - SCOPUS:80053356357

VL - 71

SP - 6195

EP - 6207

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 19

ER -